Plunkett Research Online: I-MAB

I-MAB (IMAB:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparli.....



I-MAB
Ticker: IMAB
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 86 21-6057-8000
Fax:
Address: 2440 Research Boulevard
Suite 400
Rockville, MD 20850 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
Contacts Description
Xi-Yong FuCEO/Director
Joseph SkeltonCFO
See More
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparli.....See More See More

Auditor: PricewaterhouseCoopers Zhong Tian LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021202020192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: